Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:approvalYear |
2022
|
| gptkbp:approvedBy |
gptkb:FDA
adults with intermediate or high-risk primary or secondary myelofibrosis with platelet counts below 50,000/μL |
| gptkbp:ATCCode |
L01EX20
|
| gptkbp:brand |
Vonjo
|
| gptkbp:CASNumber |
937272-79-2
|
| gptkbp:chemicalFormula |
C28H32N4O3
|
| gptkbp:contraindication |
severe hepatic impairment
|
| gptkbp:developer |
CTI BioPharma
|
| gptkbp:eliminationHalfLife |
23-26 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
pacritinib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
FLT3 inhibitor
JAK2 inhibitor |
| gptkbp:metabolism |
gptkb:CYP3A4
|
| gptkbp:molecularWeight |
472.6 g/mol
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
nausea vomiting diarrhea thrombocytopenia peripheral edema |
| gptkbp:target |
gptkb:JAK2
gptkb:FLT3 IRAK1 |
| gptkbp:usedFor |
gptkb:myelofibrosis
|
| gptkbp:bfsParent |
gptkb:JAK2
|
| gptkbp:bfsLayer |
7
|